home / stock / rsls / rsls news


RSLS News and Press, ReShape Lifesciences Inc. From 09/21/23

Stock Information

Company Name: ReShape Lifesciences Inc.
Stock Symbol: RSLS
Market: OTC
Website: reshapelifesciences.com

Menu

RSLS RSLS Quote RSLS Short RSLS News RSLS Articles RSLS Message Board
Get RSLS Alerts

News, Short Squeeze, Breakout and More Instantly...

RSLS - ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System

IRVINE, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing of an exclusive, royalty-bearing license agreement with Biorad Medysis, Pvt. Ltd. ...

RSLS - ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System

IRVINE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS) , the premier physician-led weight loss and metabolic health solutions company, today announced that the company has significantly strengthened the patent portfolio related to its Obalon ...

RSLS - ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device

IRVINE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was awarded a $331,541 Small Business Innovation Research (SBIR) grant for ...

RSLS - ReShape Lifesciences Inc. (RSLS) Q2 2023 Earnings Call Transcript

2023-08-07 22:26:13 ET ReShape Lifesciences Inc. (RSLS) Q2 2023 Earnings Conference Call August 07, 2023, 05:00 PM ET Company Participants Michael Miller - Rx Communications, IR Paul Hickey - President and CEO Tom Stankovich - CFO Christine Ren-Fielding - Mem...

RSLS - ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update

Company Executing Its Plan for Growth; Achieves Continued Improvement in Operational Effectiveness Reducing Second Quarter Operating Expenses by 53% Compared to Second Quarter of 2022 Conference Call to be Held at 5:00 pm ET Today SAN CLEMENTE, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE)...

RSLS - ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update

IRVINE, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the second quarter ended June 30, 2023, including a c...

RSLS - New Investing Ideas in Biotech: AGLE, MRTX, SXTP, AZTR, KPRX, RSLS, GENFF

2023-07-07 11:10:00 ET Vancouver, Kelowna, Delta, BC - July 7, 2023 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech. Today's stocks have been added to our lists of free stock ...

RSLS - ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software

IRVINE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing of a preferred partner agreement with Hive Medical (Hive). Hive’s software suite...

RSLS - ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device at the ASMBS 2023 Annual Meeting

IRVINE, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today presented data on its proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device in an e-po...

RSLS - COHR and RIDE among pre-market losers

2023-06-28 08:18:51 ET AST SpaceMobile ( ASTS ) -30% on pricing upsized $59.4M equity offering. American Rebel Holdings ( AREB ) -27% . Eton Pharmaceuticals ( ETON ) -15% as FDA rejects methanol poisoning therapy . Centogene ( CNTG ) -12% ...

Previous 10 Next 10